In yesterday’s Wall Street session, Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) shares traded at $1.03, up 6.02% from the previous session.
SPPI stock price is now -0.82% away from the 50-day moving average and 38.83% away from the 200-day moving average. The market capitalization of the company currently stands at $199.40M.
In other news, Brennan Nora, CFO sold 32,387 shares of the company’s stock on May 26. The stock was sold for $35,496 at an average price of $1.10. Upon completion of the transaction, the CFO now directly owns 567,828 shares in the company, valued at $0.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 15, CEO & President Riga Thomas J sold 31,381 shares of the business’s stock. A total of $24,979 was realized by selling the stock at an average price of $0.80. This leaves the insider owning 472,411 shares of the company worth $0.49 million. Insiders disposed of 460,129 shares of company stock worth roughly $0.47 million over the past 1 year. A total of 1.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SPPI stock. A new stake in Spectrum Pharmaceuticals Inc. shares was purchased by BRIDGEWAY CAPITAL MANAGEMENT, LLC during the first quarter worth $155,000. EXODUSPOINT CAPITAL MANAGEMENT, LP invested $25,000 in shares of SPPI during the first quarter. In the first quarter, WEST MICHIGAN ADVISORS, LLC acquired a new stake in Spectrum Pharmaceuticals Inc. valued at approximately $18,000. TRADITION WEALTH MANAGEMENT, LLC acquired a new stake in SPPI for approximately $5,000. In total, there are 92 active investors with 26.30% ownership of the company’s stock.
On Friday morning Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) stock kicked off with the opening price of $0.9715. During the past 12 months, Spectrum Pharmaceuticals Inc. has had a low of $0.31 and a high of $1.57. As of last week, the company has a debt-to-equity ratio of 1.07, a current ratio of 2.70, and a quick ratio of 2.40. The fifty day moving average price for SPPI is $1.0360 and a two-hundred day moving average price translates $0.7452 for the stock.
The latest earnings results from Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.02, beating analysts’ expectations of -$0.06 by 0.04. This compares to $0.00 EPS in the same period last year. For the current quarter, analysts expect SPPI to generate $16.52M in revenue.
Spectrum Pharmaceuticals Inc.(SPPI) Company Profile
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
